cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
One domain is a lectin that binds cell surface galactosyl residues and enables the protein to enter cells. The second domain is an N-glycosidase that cleaves nucleobases from ribosomal RNA, resulting in inhibition of protein synthesis and cell death. Abrin from the jequirity pea is similar.
In 2021, it was registered that shaping the electrical field could trigger a natural neurological mechanism of lateral or surround inhibition, leading to fast-onset sub-perception Spinal cord stimulation. Lateral inhibition promotes refining somatosensory information. Ascending dorsal root ganglia (DRG) fibers transmit excitatory impulses to higher-order neurons and inhibitory interneurons, which communicate with neighboring relay neurons. Thus, neurons encircling the primary target of an ascending stimulated DRG axon are inhibited, which decreases the "noise" in the system and induces higher-order neurons to trigger only when they obtain a strong and consistent signal. Further progress was made in 2022, with study results on adjusting stimulation fields to preferentially target dorsal horn dendrites, a key site for initial pain processing, rather than axons.
The Socialist Party of Albania emerged in the aftermath of the fall of communism in Albania that had dominated Albanian politics since the end of World War II. The dissolution of the People's Socialist Republic prompted a reevaluation of political ideologies and a quest for democratic governance, paving the way for the rise of multiple political entities. The roots of the Socialist Party can be traced back to the Party of Labour of Albania under its founder Enver Hoxha, which had been the ruling party for over four decades. Hoxha's successor Ramiz Alia was forced to introduce limited reforms in the late 1980s. On 11 December 1990, Alia announced that the PPSh had given up its monopoly of power. The PPSh won the 1991 Albanian Constitutional Assembly election, the first free elections held in the country in almost 80 years. By this time, it was no longer a Marxist–Leninist party. At an extraordinary congress on 10–13 June 1991, the PPSh reorganized as the PS in an effort to adapt to survive in the new system. Fatos Nano, a man from the intelligentsia, was elected the new chairman. Nano helped to reform the old Communist party and made it a member of the Socialist International. A faction of the party, led by Ilir Meta, split away from the PS in 2004 and formed the Socialist Movement for Integration (Lëvizja Socialiste për Integrim, LSI). On 10 October 2005, Nano resigned as the chairman of the PS after losing the 2005 Albanian parliamentary election, and was succeeded by Edi Rama.
=== Food sources === Dietary selenium comes from nuts, cereals, meat, mushrooms, fish, and eggs. Brazil nuts are the richest ordinary dietary source and could cause selenium toxicity if consumed regularly – though the actual concentration of selenium (as with any plant-based food sources, such as another selenium-accumulating "paradise nut" Lecythis, belonging to the same family Lecythidaceae) is soil-dependent and may vary significantly by geographic location. In descending order of concentration, high levels are also found in kidney, tuna, crab, and lobster. The human body's content of selenium is believed to be in the 13–20 milligram range.
However, some psychiatrists recommend these drugs, citing research suggesting they are equally potent with less potential for abuse. Orexin receptor antagonists like suvorexant were introduced in the 2010s and 2020s.
Sources: en.wikipedia.org
All the secondary ions generated in SIMS analysis originate from the topmost monolayers of the bombarded solid. This means that all different modes of SIMS analysis are basically surface analysis; secondary-ion emissions—atomic as well as molecular—reflect the chemical composition of the near-surface region of the bombarded solid. However, the intention of different SIMS analyses may be quite different. This depends on the erosion rate of the surface, which is controlled by the dose of the primary ions. It may be bulk analysis (dynamic SIMS) or a true analysis of originally uppermost monolayer of a condensed phase (static SIMS).
== Mathematics == Chain (ordered set), a totally ordered set, usually a subset of a given partially ordered set Chain (algebraic topology), a formal linear combination of k-simplices Chain complex, a generalization of the algebraic topology construct to homological algebra Chain rule, a tool for differentiation in calculus Chain sequence, numbers in the mathematical study of continued fractions Conway chained arrow notation, a way of expressing exponents using arrows Jordan chain, a sequence of linearly independent generalized eigenvectors of descending rank Markov chain, a discrete-time stochastic process with the Markov property Pseudo-arc, which has at its heart the concept of a chain
The Indian Plate survives as peninsular India, the oldest and geologically most stable part of the country. It extends as far north as the Satpura and Vindhya ranges in central India. These parallel chains run from the Arabian Sea coast in Gujarat in the west to the coal-rich Chota Nagpur Plateau in Jharkhand in the east. To the south, the peninsular landmass, the Deccan Plateau, is flanked on the west and east by coastal ranges known as Western and Eastern Ghats; the plateau contains the country's oldest rock formations, some over one billion years old. Geographically, India lies to the north of the equator between 6° 44′ and 35° 30′ north latitude and 68° 7′ and 97° 25′ east longitude. Major Himalayan-origin rivers that substantially flow through India include the Ganges and the Brahmaputra, both of which drain into the Bay of Bengal. Important tributaries of the Ganges include the Yamuna and the Kosi. The Kosi's extremely low gradient, caused by long-term silt deposition, leads to severe floods and course changes. Major peninsular rivers, whose steeper gradients prevent extensive flooding, include the Godavari, the Mahanadi, the Kaveri, and the Krishna, which also drain into the Bay of Bengal; and the Narmada and the Tapti, which drain into the Arabian Sea. India's coastline measures 7,517 kilometres (4,700 mi) in length; of this distance, 5,423 kilometres (3,400 mi) belong to peninsular India and 2,094 kilometres (1,300 mi) to the Andaman, Nicobar, and Lakshadweep island chains.
Lipedema is a chronic medical condition that is almost exclusively found in women and results in enlargement of both legs due to deposits of fat under the skin. It is characterized by bilateral, symmetrical buildup of fat in the legs, and sometimes arms and lower trunk (includes hips, buttocks, and abdomen). Women of any weight may be affected and the fat is resistant to traditional weight-loss methods like nutritional intervention, exercise, elevation, diuretics or bariatric surgery. The feet/hands are typically spared, presenting with a raised ridge or fold of fat, possibly a "cuff" at the wrists and ankles. In earlier stages, there may be a subtle, raised ridge or fold of fat instead of distinct cuffing and sometimes in the later stages, this increased adipose above the ankle/wrist can cause the appearance of a "cuff". Approximately 50% of people with Lipedema report pain in their fat. Other common symptoms include swelling, feelings of heaviness, and easy bruising in the affected areas. Over time mobility may be reduced, and due to reduced quality of life, people often experience depression. The cause is unknown but is believed to involve genetic and hormonal factors, lipedema onset is typically associated with periods of hormonal flux like puberty, pregnancy, or menopause and it often runs in families. Other conditions that may present similarly include lipohypertrophy, chronic venous insufficiency, and lymphedema. It is commonly misdiagnosed.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.